Navigation Links
Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
Date:5/14/2008

civir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.
Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharmasset.com

Office: (609) 613-4125

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials (including, without limitation, the two additional cohorts of our ongoing Phase 1 clinical trial of R7128) and/or our development of our product candidates, the risk that R7128 shows no activity in HCV genotype 2 or 3 patients, the risk that we cannot enroll enough patients for the Phase 3 registration clinical trial for clevudine, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2007 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
10. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
11. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... --  Ventana Medical Systems, Inc.  (Ventana), a member of ... an agreement with Merck KGaA, Darmstadt, Germany ... the United States and ... division on the development and commercialization of a companion ... diagnostic assays. In alignment with Merck KGaA,s strategic approach ...
(Date:7/10/2014)... , July 10, 2014   LabStyle Innovations ... Solution, today announced the appointment of Professor ... of its Board of Directors. Prof. ... business experience to LabStyle as an entrepreneur, venture ... and corporate governance expert. He currently serves on ...
(Date:7/10/2014)... 2014 Decision Resources Group finds that over ... Food and Drug Administration,s (FDA) approval of Vifor Fresenius ... was approved by the FDA in November 2013 for ... patients on dialysis. Other key findings from ... 2014 : , ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
... leading biopharmaceutical company dedicated to the research and development ... disorders, is marking Digestive Disease Week (DDW) 2012 in ... lives of patients with Crohn,s disease. UCB will present ... "DDW is an exciting opportunity for UCB to ...
... 17, 2012  Eisai announced today that 15 abstracts highlighting new ... Annual Meeting of the American Society of Clinical Oncology (ASCO), ... 2012. These studies highlight Eisai,s current product ... and their families affected by cancer. "Our ...
Cached Medicine Technology:UCB Proudly Reinforces Long-Standing Commitment to Crohn's Disease Community at Digestive Disease Week 2012 2UCB Proudly Reinforces Long-Standing Commitment to Crohn's Disease Community at Digestive Disease Week 2012 3UCB Proudly Reinforces Long-Standing Commitment to Crohn's Disease Community at Digestive Disease Week 2012 4Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 2Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 3Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 4Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 5Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 6Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 7Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 8Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 9
(Date:7/11/2014)... Dennis Thompson HealthDay Reporter ... born with HIV who was thought to be cured by ... showing detectable levels of the AIDS-causing virus in her bloodstream, ... nearly 4 years old, had remained virus-free even though she ... Doctors had hoped her remission would open the door to ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 The ... by Types, Applications & Geography - 2018,” defines ... fiber market with an analysis and forecast of ... specialty synthetic fibers (Para aramids, meta aramids, UHMW ... others including PPS fiber, PBI fiber, PBO fiber, ...
(Date:7/11/2014)... Operators and owners stand ... fuel costs now that model 2019 will ... standards are phasing in 2014-2018 standards. ... to install new features into their vehicles ... , 2.    Efficient driveline components which reduce friction ...
(Date:7/11/2014)... Ticket Down is a reliable source for cheap ... it comes to the summer concert schedule, it just isn’t complete ... one of the biggest names in country music and one of ... on his “That’s My Kind of Night” tour featuring Lee Brice ... making through the rest of the summer and into the fall ...
(Date:7/11/2014)... 2014 Global enterprises today are shifting ... day-to-day management activities. Managed services offer these global enterprises ... economic slowdown resulted into rising operational costs to companies. ... considered to be the global market driver for expanding ... global managed services market is estimated to grow from ...
Breaking Medicine News(10 mins):Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 2Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 4Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4
... ... announcement that Newark, one of the leading electronic component distributors in the Americas, has ... , ... (PRWEB) November 17, 2009 -- NMB Technologies Corporation, a Minebea Group Company, announced today ...
... ... Seeks Users to Test, Evaluate , ... Bethesda, Md. and Northfield, Ill. (Vocus) November 17, 2009 -- The ... from SNOMED Clinical Terms® (SNOMED CT®) to the International Classification of Diseases, 9th revision, ...
... , Obesity-Attributable Health Spending to Reach ... 17 A new report ... Ken Thorpe, Ph.D., Executive Director of the Partnership to Fight Chronic ... the country will result in higher health care spending for states ...
... for the disparity need to be further explored, researchers ... without health insurance are more likely to die after ... who are insured, new research suggests. , "After ... outcomes based on insurance status," the study authors wrote. ...
... ... has been awarded this months "Editor,s Pick" by BrotherSoft in the prestigious business software ... ... desktop application has been awarded this months "Editor,s Pick" by BrotherSoft in the prestigious ...
... ... is emerging as the top business objective for employer-sponsored wellness programs around the world. ... New York ... emerging as the top business objective for employer-sponsored wellness programs around the ...
Cached Medicine News:Health News:NMB Motors Now In Stock at Newark 2Health News:U.S. National Library of Medicine Releases Draft SNOMED CT to ICD-9-CM Rules-Based Map to Support Reimbursement 2Health News:U.S. National Library of Medicine Releases Draft SNOMED CT to ICD-9-CM Rules-Based Map to Support Reimbursement 3Health News:U.S. National Library of Medicine Releases Draft SNOMED CT to ICD-9-CM Rules-Based Map to Support Reimbursement 4Health News:Obesity Rates Will Continue to Increase, Drive Health Care Costs in New Jersey in Next Decade, According to New Study 2Health News:Uninsured Trauma Patients More Likely to Die: Study 2Health News:Taskwise receives Editors Pick Award from BrotherSoft 2Health News:Taskwise receives Editors Pick Award from BrotherSoft 3Health News:Wellness Survey: Businesses Look to Wellness Programs to Improve Productivity and Lower Absenteeism Stress Cited as Top Health Risk Driving Wellness Programs Around the World 2Health News:Wellness Survey: Businesses Look to Wellness Programs to Improve Productivity and Lower Absenteeism Stress Cited as Top Health Risk Driving Wellness Programs Around the World 3Health News:Wellness Survey: Businesses Look to Wellness Programs to Improve Productivity and Lower Absenteeism Stress Cited as Top Health Risk Driving Wellness Programs Around the World 4Health News:Wellness Survey: Businesses Look to Wellness Programs to Improve Productivity and Lower Absenteeism Stress Cited as Top Health Risk Driving Wellness Programs Around the World 5Health News:Wellness Survey: Businesses Look to Wellness Programs to Improve Productivity and Lower Absenteeism Stress Cited as Top Health Risk Driving Wellness Programs Around the World 6
... ELx405 Series of microplate washers are precise, ... patented Dual-Action manifold, providing independent control of ... overfill washing and overflow protection in both ... Washer is the most precise and reliable ...
MW 96-W1 microplate washer with one wash line....
High precision microplate washer for immuno and adherent cell assays. For use with all strip types and full microplate in 96- and 384-well format in both portrait and landscape orientations....
Wellwash 384 is an efficient, rapid and reliable washing process for high-throughput screening. It has been designed to optimize the washing process and ensure the best results. Available in 384 or 9...
Medicine Products: